Pertuzumab for the treatment of breast cancer. [Review]

MedStar author(s):
Citation: Cancer Investigation. 32(8):430-8, 2014 Oct.PMID: 24921704Institution: Washington Cancer InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, Non-U.S. Gov't | ReviewSubject headings: *Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] | *Antineoplastic Agents/tu [Therapeutic Use] | *Breast Neoplasms/dt [Drug Therapy] | Animals | Antibodies, Monoclonal, Humanized/pd [Pharmacology] | Antibodies, Monoclonal, Humanized/pk [Pharmacokinetics] | Antineoplastic Agents/pd [Pharmacology] | Antineoplastic Agents/pk [Pharmacokinetics] | Female | Humans | Treatment OutcomeYear: 2014ISSN:
  • 0735-7907
Name of journal: Cancer investigationAbstract: HER2-targeted therapies have revolutionized the outcome of patients with HER2-positive breast cancer. Pertuzumab is the first in a new class of monoclonal antibodies that target the extracellular dimerization domain of HER2 receptors, also known as HER dimerization inhibitors. The development of pertuzumab and preclinical and clinical data in breast cancer are reviewed. Regulatory affairs related to pertuzumab and the recent accelerated approval granted by the FDA for the treatment of breast cancer in the neoadjuvant setting are also covered. This process opens doors for further approvals which could considerably shorten the time between initial drug development and availability.All authors: Lynce F, Swain SMFiscal year: FY2015Digital Object Identifier: Date added to catalog: 2015-03-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 24921704 Available 24921704

HER2-targeted therapies have revolutionized the outcome of patients with HER2-positive breast cancer. Pertuzumab is the first in a new class of monoclonal antibodies that target the extracellular dimerization domain of HER2 receptors, also known as HER dimerization inhibitors. The development of pertuzumab and preclinical and clinical data in breast cancer are reviewed. Regulatory affairs related to pertuzumab and the recent accelerated approval granted by the FDA for the treatment of breast cancer in the neoadjuvant setting are also covered. This process opens doors for further approvals which could considerably shorten the time between initial drug development and availability.

English

Powered by Koha